Table 3.

Association of GSTM3 genotypes with histology, lymph nodes, and location of tumor in esophageal cancer

GSTM3 AA*, n (%)GSTM3 AB+BB, n (%)
Histology
    Squamous cell carcinoma patients (n = 142)/controls (n = 200)112 (78.8%)/176 (88%)30 (21.2%)/24 (12%)
        OR (95% CI), P1 (reference)*1.9 (1.0-3.4), P = 0.03
    Adenocarcinoma patients (n = 9)/controls (n = 200)5 (55.6%)/176 (88.5%)4 (44.4%)/ 24 (11.5%)
        OR (95% CI), P1 (reference)*3.4 (1.1-10.9), P = 0.03
Lymph nodes
    Presence (n = 86)/controls (n = 200)72 (83.7%)/176 (88.5%)14 (16.3%)/24 (11.5%)
        OR (95% CI), P1 (reference)*1.6 (0.85-3.1), P = 0.13
    Absence (n = 41)/controls (n = 200)28 (68.3%)/176 (88.4%)13 (31.7%)/24 (11.5%)
        OR (95% CI), P13.1 (1.5-6.3), P = 0.001
Tumor location
    Upper (n = 21)/controls (n = 200)18 (85.7%)/176 (88.5%)3 (14.2%)/24 (11.5%)
        OR (95% CI), P1 (reference)*2.1 (0.80-5.9), P = 0.12
    Middle (n = 73)/controls (n = 200)58 (79.4%)/176 (88.5%)15 (20.5%)/24 (11.5%)
        OR (95% CI), P1 (reference)*2.2 (1.1-4.4), P = 0.01
    Lower (n = 48)/controls (n = 200)37 (77.0%)/176 (88.5%)11 (22.9%)/24 (11.5%)
        OR (95% CI), P1 (reference)*2.6 (1.2-5.6), P = 0.01
  • * Age-, gender-, smoking-, and alcohol-adjusted ORs were calculated, using GSTM3 AA as reference.